Apolipoprotein A-I (APOA1) (APOA1)

Apolipoprotein A-I (APOA1) is the primary protein component of high-density lipoprotein (HDL) particles, playing a critical role in reverse cholesterol transport by promoting the efflux of cholesterol from peripheral tissues, such as macrophages in the arterial wall, to the liver for excretion [1][2]. The APOA1 genomic locus, located on chromosome 11, is part of a gene cluster (APOA1/C3/A4/A5) that is coordinately regulated to maintain lipid homeostasis [3]. Therapeutic strategies targeting this locus include the use of BET (bromodomain and extra-terminal) inhibitors like apabetalone, which epigenetically upregulate APOA1 expression to increase HDL levels and improve cardiovascular outcomes [4][5]. Additionally, infusion of reconstituted HDL or recombinant APOA1 variants (e.g., CSL112) is being investigated to rapidly enhance cholesterol efflux in patients following acute myocardial infarction [6]. Low levels of APOA1 are strongly associated with an increased risk of atherosclerosis and coronary artery disease, while certain rare mutations in the APOA1 gene can lead to hereditary amyloidosis [7][8]. Beyond lipid transport, APOA1 exhibits anti-inflammatory and antioxidant properties that contribute to its vasoprotective effects [1].

Other names

Apo-AIApoA-IALP-1Locus for Apolipoprotein A-IAPOA1 genomic locus

Epigenetic upregulation of APOA1 gene expression via BET inhibition; direct cholesterol efflux enhancement via infusion of recombinant or reconstituted HDL; transcriptional activation via PPAR-alpha agonists.